CTOs on the Move

ICON Laboratories

www.iconlab.com

 
ICON Laboratories is a Farmingdale, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.iconlab.com
  • 123 Smith St
    Farmingdale, NY USA 11735
  • Phone: 631.306.5445

Executives

Name Title Contact Details

Similar Companies

IQuum

IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Meta Systems

Meta Systems is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OmniActive Health Technologies

OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.

Alvotech

Alvotech is a fully integrated specialty biopharmaceutical company focused on development and manufacturing of high quality biosimilar medicines.

Vascular Biogenics Limited Therapeutics

VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.